Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
- Revenue in USD (TTM)45.85bn
- Net income in USD7.31bn
- LocationBristol-Myers Squibb Co430 East 29th Street, 14th FloorNEW YORK 10016United StatesUSA
- Phone+1 (2125) 464-2000
- Fax+1 (302) 655-5049
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|BMY:NYQ since |
|Turning Point Therapeutics Inc||Deal completed||03 Jun 2022||03 Jun 2022Deal completed||-14.99%||4.08bn|